12 Health Care Stocks Moving In Friday's Pre-Market Session

Actuate Therapeutics, Inc. +7.74%
AN2 Therapeutics, Inc. +0.12%
Corvus Pharmaceuticals, Inc. -0.06%
Enveric Biosciences, Inc. +34.20%
Harvard Bioscience, Inc. +0.50%

Actuate Therapeutics, Inc.

ACTU

2.73

+7.74%

AN2 Therapeutics, Inc.

ANTX

4.29

+0.12%

Corvus Pharmaceuticals, Inc.

CRVS

16.01

-0.06%

Enveric Biosciences, Inc.

ENVB

5.39

+34.20%

Harvard Bioscience, Inc.

HBIO

6.81

+0.50%

Gainers

  • Psyence Biomedical (NASDAQ:PBM) stock rose 77.2% to $10.4 during Friday's pre-market session. The company's market cap stands at $6.0 million.
  • iSpecimen (NASDAQ:ISPC) stock rose 34.76% to $0.16. The company's market cap stands at $3.4 million.
  • Corvus Pharmaceuticals (NASDAQ:CRVS) shares increased by 14.69% to $17.25. The company's market cap stands at $1.2 billion.
  • AN2 Therapeutics (NASDAQ:ANTX) shares increased by 14.33% to $3.59. The company's market cap stands at $112.8 million.
  • Kura Oncology (NASDAQ:KURA) shares rose 12.75% to $10.08. The company's market cap stands at $793.5 million.
  • Beyond Air (NASDAQ:XAIR) shares moved upwards by 12.33% to $0.5. The market value of their outstanding shares is at $4.6 million.

Losers

  • Enveric Biosciences (NASDAQ:ENVB) shares fell 16.2% to $1.97 during Friday's pre-market session. The company's market cap stands at $3.2 million.
  • Harvard Bioscience (NASDAQ:HBIO) stock fell 10.16% to $5.31. The market value of their outstanding shares is at $26.4 million.
  • Trevi Therapeutics (NASDAQ:TRVI) shares declined by 8.88% to $13.25. The company's market cap stands at $1.8 billion.
  • Actuate Therapeutics (NASDAQ:ACTU) shares fell 8.87% to $1.96. The market value of their outstanding shares is at $50.9 million.
  • Propanc Biopharma (NASDAQ:PPCB) shares decreased by 8.0% to $0.1. The company's market cap stands at $2.3 million.
  • Hoth Therapeutics (NASDAQ:HOTH) stock declined by 7.43% to $0.69. The company's market cap stands at $14.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.